Literature DB >> 10231204

Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature.

J V Pergolizzi1, M Auster, G L Conaway, A Sardi.   

Abstract

Primary liver cancers are a significant cause of both morbidity and mortality. Although surgical resection remains the treatment of choice for these tumors, only 10 to 20 per cent of the primary liver tumors are found to be resectable. Presently, the options for these patients include liver transplantation, cryosurgery, or nonsurgical therapy, such as transarterial chemoembolization. Techniques such as alcohol injection, interstitial radiotherapy, laser hypothermia, and radiofrequency electrodissection have all been attempted with limited success. We present a case of a 68-year-old woman with a 10-year history of liver cirrhosis secondary to chronic active hepatitis C. A lateral segmentectomy was recommended but could not be done due to severe underlying cirrhosis. Cryosurgery aided by intraoperative ultrasonography was performed successfully. The patient developed recurrent disease at 58 months and died with disease at 62 months. Advances in instrumentation and intraoperative ultrasonography are making cryosurgery a viable surgical therapeutic alternative in the management of patients with unresectable hepatocellular carcinoma. The procedure can be performed safely with low morbidity.

Entities:  

Mesh:

Year:  1999        PMID: 10231204

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

1.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.

Authors:  Z W Zhu; H Friess; L Wang; M Abou-Shady; A Zimmermann; A D Lander; M Korc; J Kleeff; M W Büchler
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

2.  CT- versus coregistered FDG-PET/CT-based radiation therapy plans for conformal radiotherapy in colorectal liver metastases: a dosimetric comparison.

Authors:  Cem Parlak; Erkan Topkan; Serhat Sonmez; Cem Onal; Mehmet Reyhan
Journal:  Jpn J Radiol       Date:  2012-06-30       Impact factor: 2.374

3.  Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells.

Authors:  Yan-Ming Zhou; Yin-Hao Wen; Xiao-Yan Kang; Hai-Hua Qian; Jia-Mei Yang; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

4.  Research on the interaction between tubeimoside 1 and HepG2 cells using the microscopic imaging and fluorescent spectra method.

Authors:  Xiaogang Lin; Wenchao Li; Changbin Ye; Xiaozhu Liu; Hao Zhu; Wenbing Peng; Jie Rong
Journal:  Comput Math Methods Med       Date:  2014-05-14       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.